Evidence map›Paper›PMID 35531514›Full record

ArticleRSC advances2019

Synthesis and bioevaluation of thienopyrimidines bearing a pyrazoline unit as selective PI3Kα inhibitors.

Luogen Lai, Qinqin Wang, Binliang Zhang, Zhen Xiao, Zunhua Yang, Qi Yang, Zixin Luo, Wufu Zhu, Shan Xu

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Luogen LaiJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University Nanchang 330013 China zhuwufu-1122@163.com shanxu9891@126.com +86 791 8380-2393 +86 791 8380-2393.
Qinqin WangJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University Nanchang 330013 China zhuwufu-1122@163.com shanxu9891@126.com +86 791 8380-2393 +86 791 8380-2393.
Binliang ZhangJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University Nanchang 330013 China zhuwufu-1122@163.com shanxu9891@126.com +86 791 8380-2393 +86 791 8380-2393.
Zhen XiaoJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University Nanchang 330013 China zhuwufu-1122@163.com shanxu9891@126.com +86 791 8380-2393 +86 791 8380-2393.
Zunhua YangCollege of Pharmacy, Jiangxi University of Traditional Chinese Medicine Nanchang 330004 China.
Qi YangJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University Nanchang 330013 China zhuwufu-1122@163.com shanxu9891@126.com +86 791 8380-2393 +86 791 8380-2393.
Zixin LuoJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University Nanchang 330013 China zhuwufu-1122@163.com shanxu9891@126.com +86 791 8380-2393 +86 791 8380-2393.
Wufu ZhuJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University Nanchang 330013 China zhuwufu-1122@163.com shanxu9891@126.com +86 791 8380-2393 +86 791 8380-2393.ORCID https://orcid.org/0000-0001-6075-0450
Shan XuJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University Nanchang 330013 China zhuwufu-1122@163.com shanxu9891@126.com +86 791 8380-2393 +86 791 8380-2393.
Jiangxi Science and Technology Normal University · CNJiangxi University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of thienopyrimidines containing a pyrazoline unit (4a-d, 7a-d and 13a-l) were designed and synthesized. The target compounds were evaluated for antiproliferative activity against A549, HepG2 and MCF-7 cancer cell lines. Among the twenty target compounds, most of them exhibited excellent antiproliferative activity against one or several cancer cell lines. Compound 13f showed the best activity against A549, MCF-7 and HepG2 cancer cell lines, with IC

Identifiers

PMID35531514
PMCPMC9072010
OpenAlexW2973555272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.